Top Page
BeiGene Ltd
(6160)
BeiGene Ltd (6160) vs. iShares MSCI Hong Kong ETF (EWH)
BeiGene Ltd Business Overview & Revenue Model
BeiGene Ltd Earnings Call Summary
BeiGene Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.56B | 3.81B | 2.46B | 1.42B | 1.18B | 308.87M |
| Gross Profit | 3.90B | 3.22B | 2.08B | -511.06M | -447.86M | -1.06B |
| EBITDA | 89.25M | -396.44M | -1.12B | -1.72B | -1.39B | -1.63B |
| Net Income | -177.64M | -644.79M | -881.71M | -2.00B | -1.46B | -1.62B |
Balance Sheet | ||||||
| Total Assets | 6.30B | 5.92B | 5.81B | 6.38B | 8.65B | 5.60B |
| Cash, Cash Equivalents and Short-Term Investments | 2.76B | 2.63B | 3.17B | 4.53B | 6.62B | 4.65B |
| Total Debt | 1.03B | 1.08B | 930.18M | 596.67M | 694.64M | 561.96M |
| Total Liabilities | 2.53B | 2.59B | 2.27B | 2.00B | 2.40B | 1.73B |
| Stockholders Equity | 3.77B | 3.33B | 3.54B | 4.38B | 6.24B | 3.87B |
Cash Flow | ||||||
| Free Cash Flow | 164.84M | -669.77M | -1.75B | -1.97B | -1.61B | -1.51B |
| Operating Cash Flow | 571.21M | -140.63M | -1.16B | -1.50B | -1.30B | -1.28B |
| Investing Cash Flow | -416.03M | -548.35M | 60.00M | 1.08B | 640.66M | -3.17B |
| Financing Cash Flow | 9.39M | 193.45M | 416.48M | -18.97M | 3.64B | 5.20B |
BeiGene Ltd Technical Analysis
BeiGene Ltd Risk Analysis
BeiGene Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$283.51B | ― | -4.94% | ― | 46.78% | 66.53% | |
51 Neutral | $7.85B | -0.18 | -40.01% | 2.28% | 22.97% | -2.05% | |
| ― | $19.94B | 125.92 | 8.41% | ― | ― | ― | |
| ― | $17.33B | 30.75 | 9.79% | ― | ― | ― | |
83 Outperform | HK$300.41B | 20.12 | 23.23% | 0.37% | 6.94% | 42.86% | |
73 Outperform | HK$216.29B | 40.92 | 16.09% | 0.94% | 8.68% | 0.82% | |
| ― | HK$478.57B | 65.56 | 14.44% | 0.36% | ― | ― |
BeiGene Ltd Corporate Events
BeOne Medicines Ltd., a Swiss corporation, announced it will release its unaudited financial results for the second quarter of 2025 on August 6, 2025, following the trading hours of the Hong Kong Stock Exchange. The results, prepared in accordance with U.S. GAAP, will be reviewed by the company’s audit committee. A conference call with management will follow the release, and an archived webcast will be available on the company’s website. The interim results will also be announced in compliance with the HK Listing Rules by August 29, 2025, including a reconciliation from U.S. GAAP to IFRS.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd., a corporation incorporated under the laws of Switzerland, announced the grant of Restricted Share Units (RSUs) under its 2016 Share Option and Incentive Plan. On June 30, 2025, the company’s compensation committee granted a total of 43,839 RSUs, representing 569,907 underlying shares, to 216 grantees. This grant accounts for approximately 0.04% of the total issued shares. The RSUs will vest over four years, with specific conditions for accelerated vesting in certain cases. This move is part of the company’s ongoing efforts to incentivize and retain its employees.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd., a company incorporated under Swiss law, has announced the granting of share options, restricted share units (RSUs), and performance share units (PSUs) under its 2016 Share Option and Incentive Plan. The grants include options for 147,355 American Depositary Shares (ADSs) to 31 grantees, RSUs for 1,720,092 ADSs to 9,012 grantees, and PSUs for 141,377 ADSs to 30 grantees. This move is part of the company’s strategy to incentivize and retain talent, aligning employee interests with shareholder value. The options have a ten-year validity, with a structured vesting schedule and a clawback mechanism to ensure compliance with company policies.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd., a Switzerland-based corporation, announced the grant of share options and restricted share units under its 2016 Share Option and Incentive Plan. The compensation committee granted options to subscribe for 21,140 American Depositary Shares (ADSs) to two grantees and restricted share units involving 54,538 ADSs to 368 grantees. This move is part of the company’s strategy to incentivize and retain talent, potentially impacting its operational efficiency and market competitiveness.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$206.60 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeiGene Ltd, operating under the stock code 06160, has released an information sheet detailing various waivers and exemptions they have sought from compliance with certain Hong Kong Exchange Listing Rules. These waivers pertain to aspects such as the use of US GAAP, auditing standards, and specific shareholder approval requirements. The company’s directors affirm the accuracy of the information and commit to updating it as necessary. This release highlights BeiGene’s strategic efforts to navigate regulatory frameworks, potentially impacting its operational flexibility and stakeholder engagements.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd. has established a Commercial and Medical Affairs Advisory Committee to assist its Board of Directors in overseeing and advising on the company’s commercial and medical affairs activities. This committee will play a crucial role in shaping the strategic direction of BeOne’s commercial operations and medical affairs, ensuring alignment with the company’s overall goals and enhancing its competitive position in the market.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd. has outlined the purpose and structure of its Audit Committee, which is responsible for overseeing the integrity of the company’s financial reporting, the qualifications and performance of its independent auditors, and compliance with legal and regulatory requirements. The committee is composed of independent directors with financial expertise, meeting at least quarterly to ensure robust governance and accountability in financial matters, which is crucial for maintaining stakeholder trust and regulatory compliance.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd. has established a Compensation Committee to oversee the company’s executive compensation plans, policies, and programs. The committee’s primary goal is to attract and retain key management personnel, align management interests with shareholders, and ensure effective talent management and succession planning. The committee is responsible for reviewing and recommending director and executive compensation and producing reports for shareholder meetings, thereby impacting the company’s governance and operational efficiency.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd. has outlined the responsibilities and structure of its Nominating and Corporate Governance Committee. The committee is tasked with identifying qualified individuals for the Board, recommending director nominees, developing corporate governance guidelines, and overseeing annual evaluations of the Board and its committees. Composed entirely of independent directors as per NASDAQ rules, the committee plays a crucial role in maintaining and enhancing the company’s governance framework.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd. has established a Scientific Advisory Committee to enhance its board’s oversight of research and development activities, providing strategic scientific guidance. This move aims to bolster the company’s R&D capabilities, ensuring alignment with its strategic goals, and potentially strengthening its position within the pharmaceutical industry.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd., a Swiss corporation, has issued an overseas regulatory announcement regarding a post-effective amendment to Form S-4, which has been filed with the U.S. Securities and Exchange Commission. This announcement, made under the rules governing the listing of securities on The Stock Exchange of Hong Kong Limited, indicates administrative updates in compliance with regulatory requirements, potentially impacting the company’s operational transparency and regulatory adherence.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd., a Switzerland-based company, has announced a post-effective amendment to its Form S-3 registration statement filed with the U.S. Securities and Exchange Commission. This move allows the company to offer securities on a delayed or continuous basis under Rule 415 of the Securities Act of 1933, potentially enhancing its financial flexibility and market presence.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd. has issued a post-effective amendment to its Form S-3 registration statement, filed with the U.S. Securities and Exchange Commission. This amendment indicates the company’s intention to offer securities on a delayed or continuous basis, suggesting strategic financial maneuvers to support its operations and growth. This move could potentially impact the company’s market positioning and provide opportunities for stakeholders.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd., a company incorporated under Swiss law, has announced a post-effective amendment to its Form S-8 registration statement filed with the U.S. Securities and Exchange Commission. This amendment pertains to various share option and incentive plans, reflecting the company’s ongoing regulatory compliance and commitment to maintaining transparent financial operations. The announcement highlights the company’s active engagement with international regulatory standards, which may bolster its credibility and attractiveness to investors.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd., a Swiss corporation, has made an overseas regulatory announcement regarding its Form 8-K12G3 filing with the U.S. Securities and Exchange Commission. This filing, dated May 27, 2025, is part of the company’s compliance with the Securities Exchange Act of 1934. The announcement underscores BeOne Medicines’ commitment to maintaining transparency and regulatory compliance, which may impact its market perception and investor confidence.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd., formerly known as BeiGene, Ltd., has announced its official continuation as a Swiss stock corporation, effective May 27, 2025. This transition includes the adoption of new Swiss Articles, the appointment of Ernst & Young AG as the Swiss statutory auditor, and a change in the company’s English name and website. The move signifies a strategic shift in the company’s operational base and corporate identity, potentially impacting its market positioning and stakeholder engagement.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeiGene, Ltd. announced the grant of share options and restricted share units to nine independent non-executive directors (INEDs) under its 2016 Share Option and Incentive Plan. The grants, which involve a total of 15,750 American Depositary Shares (ADSs) for options and 7,605 ADSs for restricted share units, are part of the compensation package for INEDs. This initiative aims to align the directors’ interests with the company’s long-term strategy and development, motivating them to contribute effectively to the company’s growth. The options have a ten-year validity period and are subject to accelerated vesting under certain conditions, reflecting the company’s commitment to retaining and incentivizing key personnel.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeiGene Ltd announced the grant of 42,009 Restricted Share Units (RSUs) to 192 employees under its 2016 Share Option and Incentive Plan. These RSUs, representing approximately 0.04% of the total issued shares, are part of the company’s strategy to incentivize and retain talent. The vesting of these RSUs is structured over a four-year period, reflecting BeiGene’s commitment to long-term employee engagement and alignment with company goals.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeiGene, Ltd. announced the issuance of 133,000,000 new shares under its 2016 Share Option and Incentive Plan to BGNC2, a wholly-owned subsidiary, to satisfy equity awards for approximately 10,900 grantees, including directors, officers, employees, and consultants. This strategic move is part of BeiGene’s long-term growth objectives, with plans to continue its holding company in Switzerland, ensuring no dilutive impact on shareholders and avoiding Swiss taxes on the new shares.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeiGene, Ltd. has released its quarterly report for the period ending March 31, 2025, filed with the U.S. Securities and Exchange Commission. The report indicates compliance with all necessary filing requirements, reflecting the company’s ongoing commitment to transparency and regulatory adherence. This announcement underscores BeiGene’s robust operational framework and its strategic positioning in the global biotechnology market, particularly in the U.S. and China.
BeiGene, Ltd. announced its unaudited financial results for the first quarter of 2025, highlighting key business updates and reaffirming its financial guidance for the year. The company emphasized its commitment to achieving significant milestones in oncology innovation, with implications for its market positioning and stakeholder interests.